Cary C Cotton1, Rehan Haidry2, Aaron P Thrift3, Laurence Lovat2, Nicholas J Shaheen4. 1. University of North Carolina at Chapel Hill, Department of Medicine, Division of Gastroenterology and Hepatology, Center for Esophageal Diseases and Swallowing, Chapel Hill, North Carolina. 2. University College Hospital, Department of Gastroenterology, Fitzrovia, London, UK; Division of Surgery & Interventional Science, University College London, London, UK. 3. Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, Texas; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas. 4. University of North Carolina at Chapel Hill, Department of Medicine, Division of Gastroenterology and Hepatology, Center for Esophageal Diseases and Swallowing, Chapel Hill, North Carolina. Electronic address: nshaheen@med.unc.edu.
Abstract
BACKGROUND & AIMS: Barrett's esophagus (BE) recurs in 25% or more of patients treated successfully with radiofrequency ablation (RFA), so surveillance endoscopy is recommended after complete eradication of intestinal metaplasia (CEIM). The frequency of surveillance is informed only by expert opinion. We aimed to model the incidence of neoplastic recurrence, validate the model in an independent cohort, and propose evidence-based surveillance intervals. METHODS: We collected data from the United States Radiofrequency Ablation Registry (US RFA, 2004-2013) and the United Kingdom National Halo Registry (UK NHR, 2007-2015) to build and validate models to predict the incidence of neoplasia recurrence after initially successful RFA. We developed 3 categories of risk and modeled intervals to yield 0.1% risk of recurrence with invasive adenocarcinoma. We fit Cox proportional hazards models assessing discrimination by C statistic and 95% confidence limits. RESULTS: The incidence of neoplastic recurrence was associated with most severe histologic grade before CEIM, age, endoscopic mucosal resection, sex, and baseline BE segment length. In multivariate analysis, a model based solely on most severe pre-CEIM histology predicted neoplastic recurrence with a C statistic of 0.892 (95% confidence limit, 0.863-0.921) in the US RFA registry. This model also performed well when we used data from the UK NHR. Our model divided patients into 3 risk groups based on baseline histologic grade: non-dysplastic BE; indefinite for dysplasia, low-grade dysplasia, and high-grade dysplasia; or intramucosal adenocarcinoma. For patients with low-grade dysplasia, we propose surveillance endoscopy at 1 and 3 years after CEIM; for patients with high-grade dysplasia or intramucosal adenocarcinoma, we propose surveillance endoscopy at 0.25, 0.5, and 1 year after CEIM, then annually. CONCLUSION: In analyses of data from the US RFA and UK NHR for BE, a much-attenuated schedule of surveillance endoscopy would provide protection from invasive adenocarcinoma. Adherence to the recommended surveillance intervals could decrease the number of endoscopies performed yet identify unresectable cancers at rates less than 1/1000 endoscopies.
BACKGROUND & AIMS: Barrett's esophagus (BE) recurs in 25% or more of patients treated successfully with radiofrequency ablation (RFA), so surveillance endoscopy is recommended after complete eradication of intestinal metaplasia (CEIM). The frequency of surveillance is informed only by expert opinion. We aimed to model the incidence of neoplastic recurrence, validate the model in an independent cohort, and propose evidence-based surveillance intervals. METHODS: We collected data from the United States Radiofrequency Ablation Registry (US RFA, 2004-2013) and the United Kingdom National Halo Registry (UK NHR, 2007-2015) to build and validate models to predict the incidence of neoplasia recurrence after initially successful RFA. We developed 3 categories of risk and modeled intervals to yield 0.1% risk of recurrence with invasive adenocarcinoma. We fit Cox proportional hazards models assessing discrimination by C statistic and 95% confidence limits. RESULTS: The incidence of neoplastic recurrence was associated with most severe histologic grade before CEIM, age, endoscopic mucosal resection, sex, and baseline BE segment length. In multivariate analysis, a model based solely on most severe pre-CEIM histology predicted neoplastic recurrence with a C statistic of 0.892 (95% confidence limit, 0.863-0.921) in the US RFA registry. This model also performed well when we used data from the UK NHR. Our model divided patients into 3 risk groups based on baseline histologic grade: non-dysplastic BE; indefinite for dysplasia, low-grade dysplasia, and high-grade dysplasia; or intramucosal adenocarcinoma. For patients with low-grade dysplasia, we propose surveillance endoscopy at 1 and 3 years after CEIM; for patients with high-grade dysplasia or intramucosal adenocarcinoma, we propose surveillance endoscopy at 0.25, 0.5, and 1 year after CEIM, then annually. CONCLUSION: In analyses of data from the US RFA and UK NHR for BE, a much-attenuated schedule of surveillance endoscopy would provide protection from invasive adenocarcinoma. Adherence to the recommended surveillance intervals could decrease the number of endoscopies performed yet identify unresectable cancers at rates less than 1/1000 endoscopies.
Authors: K Nadine Phoa; Roos E Pouw; Frederike G I van Vilsteren; Carine M T Sondermeijer; Fiebo J W Ten Kate; Mike Visser; Sybren L Meijer; Mark I van Berge Henegouwen; Bas L A M Weusten; Erik J Schoon; Rosalie C Mallant-Hent; Jacques J G H M Bergman Journal: Gastroenterology Date: 2013-03-28 Impact factor: 22.682
Authors: Corey S Johnson; Brian E Louie; Aaron Wille; Christy M Dunst; Stephanie G Worrell; Steven R DeMeester; Jessica Reynolds; Joe Dixon; John C Lipham; Michal Lada; Jeffrey H Peters; Thomas J Watson; Alexander S Farivar; Ralph W Aye Journal: J Gastrointest Surg Date: 2015-03-05 Impact factor: 3.452
Authors: Sarina Pasricha; William J Bulsiewicz; Kelly E Hathorn; Srinadh Komanduri; V Raman Muthusamy; Richard I Rothstein; Herbert C Wolfsen; Charles J Lightdale; Bergein F Overholt; Daniel S Camara; Evan S Dellon; William D Lyday; Atilla Ertan; Gary W Chmielewski; Nicholas J Shaheen Journal: Clin Gastroenterol Hepatol Date: 2014-05-09 Impact factor: 11.382
Authors: Eric S Orman; Hannah P Kim; William J Bulsiewicz; Cary C Cotton; Evan S Dellon; Melissa B Spacek; Xiaoxin Chen; Ryan D Madanick; Sarina Pasricha; Nicholas J Shaheen Journal: Am J Gastroenterol Date: 2012-12-18 Impact factor: 10.864
Authors: J K Lee; R G Cameron; K F Binmoeller; J N Shah; A Shergill; R Garcia-Kennedy; Y M Bhat Journal: Endoscopy Date: 2013-04-16 Impact factor: 10.093
Authors: Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale Journal: N Engl J Med Date: 2009-05-28 Impact factor: 91.245
Authors: R J Haidry; M A Butt; J M Dunn; A Gupta; G Lipman; H L Smart; P Bhandari; L Smith; R Willert; G Fullarton; M Di Pietro; C Gordon; I Penman; H Barr; P Patel; N Kapoor; J Hoare; R Narayanasamy; Y Ang; A Veitch; K Ragunath; M Novelli; L B Lovat Journal: Gut Date: 2014-12-24 Impact factor: 23.059
Authors: Heng Lu; Ajaz A Bhat; Dunfa Peng; Zheng Chen; Shoumin Zhu; Jun Hong; Selma Maacha; Jin Yan; David J Robbins; M Kay Washington; Abbes Belkhiri; Wael El-Rifai Journal: Cancer Res Date: 2019-07-15 Impact factor: 12.701
Authors: Durayd Alzoubaidi; Krish Ragunath; Sachin Wani; Ian D Penman; Nigel John Trudgill; Marnix Jansen; Matthew Banks; Pradeep Bhandari; Allan John Morris; Robert Willert; Phil Boger; Howard L Smart; Narayanasamy Ravi; Jason Dunn; Charles Gordon; Jayan Mannath; Inder Mainie; Massi di Pietro; Andrew M Veitch; Sally Thorpe; Cormac Magee; Martin Everson; Sarmed Sami; Paul Bassett; David Graham; Stephen Attwood; Oliver Pech; Prateek Sharma; Laurence B Lovat; Rehan Haidry Journal: Frontline Gastroenterol Date: 2019-08-14